Glaukos Corp Stock Performance
| GKOS Stock | USD 100.38 0.86 0.85% |
The company retains a Market Volatility (i.e., Beta) of 1.68, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Glaukos Corp will likely underperform. At this point, Glaukos Corp has a negative expected return of -0.58%. Please make sure to check out Glaukos Corp's potential upside, and the relationship between the jensen alpha and rate of daily change , to decide if Glaukos Corp performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Glaukos Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return (0.63) | Five Day Return 2.74 | Year To Date Return (32.79) | Ten Year Return 222.23 | All Time Return 222.23 |
1 | Acquisition by Alex Thurman of 3660 shares of Glaukos Corp at 55.18 subject to Rule 16b-3 | 12/30/2024 |
2 | Disposition of 4059 shares by Thomas Burns of Glaukos Corp at 138.93 subject to Rule 16b-3 | 01/02/2025 |
3 | Disposition of 529 shares by Thomas Burns of Glaukos Corp at 92.69 subject to Rule 16b-3 | 01/10/2025 |
4 | Disposition of 529 shares by Thomas Burns of Glaukos Corp at 93.57 subject to Rule 16b-3 | 01/17/2025 |
5 | Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20 | 01/23/2025 |
6 | Acquisition by Aimee Weisner of 25000 shares of Glaukos Corp at 32.0 subject to Rule 16b-3 | 02/07/2025 |
7 | Glaukos Posts Earnings Results, Misses Expectations By 0.02 EPS | 02/21/2025 |
8 | FDA Sets Decision Date For Glaukos Keratoconus Treatment Without The Need Of Surgery | 02/24/2025 |
9 | Glaukos Corp Announces FDA Review of Epioxa NDA for Keratoconus Treatment | 02/25/2025 |
10 | Disposition of 15000 shares by Mark Foley of Glaukos Corp at 24.69 subject to Rule 16b-3 | 02/26/2025 |
11 | Illinois Municipal Retirement Fund Has 4.41 Million Position in Glaukos Co. | 02/27/2025 |
12 | Acquisition by Joseph Gilliam of 2275 shares of Glaukos Corp at 69.3 subject to Rule 16b-3 | 02/28/2025 |
13 | Is Glaukos Corporation the Best Medical Technology Stock to Buy According to Analysts | 03/05/2025 |
14 | Acquisition by Gilbert Kliman of 5000 shares of Glaukos Corp at 32.0 subject to Rule 16b-3 | 03/10/2025 |
15 | RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire A Next-Generation Visual Field Solution | 03/11/2025 |
16 | Glaukos Corp Trading 3.36 percent Higher on Mar 12 | 03/12/2025 |
17 | Heres Why You Should Retain Glaukos Stock in Your Portfolio | 03/13/2025 |
18 | Disposition of 958 shares by Tomas Navratil of Glaukos Corp at 102.19 subject to Rule 16b-3 | 03/17/2025 |
| Begin Period Cash Flow | 99.3 M |
Glaukos |
Glaukos Corp Relative Risk vs. Return Landscape
If you would invest 15,088 in Glaukos Corp on December 20, 2024 and sell it today you would lose (4,964) from holding Glaukos Corp or give up 32.9% of portfolio value over 90 days. Glaukos Corp is currently does not generate positive expected returns and assumes 3.8358% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than Glaukos, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Glaukos Corp Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Glaukos Corp's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Glaukos Corp, and traders can use it to determine the average amount a Glaukos Corp's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1525
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GKOS |
Estimated Market Risk
| 3.84 actual daily | 34 66% of assets are more volatile |
Expected Return
| -0.58 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.15 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Glaukos Corp is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Glaukos Corp by adding Glaukos Corp to a well-diversified portfolio.
Glaukos Corp Fundamentals Growth
Glaukos Stock prices reflect investors' perceptions of the future prospects and financial health of Glaukos Corp, and Glaukos Corp fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Glaukos Stock performance.
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.0706 | ||||
| Profit Margin | (0.38) % | ||||
| Operating Margin | (0.27) % | ||||
| Current Valuation | 5.51 B | ||||
| Shares Outstanding | 56.57 M | ||||
| Price To Earning | 94.70 X | ||||
| Price To Book | 7.47 X | ||||
| Price To Sales | 14.93 X | ||||
| Revenue | 383.48 M | ||||
| Gross Profit | 289.45 M | ||||
| EBITDA | (95.64 M) | ||||
| Net Income | (146.37 M) | ||||
| Cash And Equivalents | 391.19 M | ||||
| Cash Per Share | 8.22 X | ||||
| Total Debt | 103.4 M | ||||
| Debt To Equity | 0.68 % | ||||
| Current Ratio | 6.78 X | ||||
| Book Value Per Share | 13.59 X | ||||
| Cash Flow From Operations | (61.32 M) | ||||
| Earnings Per Share | (2.77) X | ||||
| Market Capitalization | 5.73 B | ||||
| Total Asset | 974.76 M | ||||
| Retained Earnings | (745.44 M) | ||||
| Working Capital | 374.67 M | ||||
| Current Asset | 104.14 M | ||||
| Current Liabilities | 20.36 M | ||||
About Glaukos Corp Performance
Assessing Glaukos Corp's fundamental ratios provides investors with valuable insights into Glaukos Corp's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Glaukos Corp is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 223.90 | 148.73 | |
| Return On Tangible Assets | (0.23) | (0.24) | |
| Return On Capital Employed | (0.14) | (0.14) | |
| Return On Assets | (0.15) | (0.16) | |
| Return On Equity | (0.19) | (0.18) |
Things to note about Glaukos Corp performance evaluation
Checking the ongoing alerts about Glaukos Corp for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Glaukos Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Glaukos Corp generated a negative expected return over the last 90 days | |
| Glaukos Corp has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 383.48 M. Net Loss for the year was (146.37 M) with profit before overhead, payroll, taxes, and interest of 289.45 M. | |
| Glaukos Corp currently holds about 391.19 M in cash with (61.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.22. | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 958 shares by Tomas Navratil of Glaukos Corp at 102.19 subject to Rule 16b-3 |
- Analyzing Glaukos Corp's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Glaukos Corp's stock is overvalued or undervalued compared to its peers.
- Examining Glaukos Corp's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Glaukos Corp's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Glaukos Corp's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Glaukos Corp's stock. These opinions can provide insight into Glaukos Corp's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Glaukos Stock Analysis
When running Glaukos Corp's price analysis, check to measure Glaukos Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Glaukos Corp is operating at the current time. Most of Glaukos Corp's value examination focuses on studying past and present price action to predict the probability of Glaukos Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Glaukos Corp's price. Additionally, you may evaluate how the addition of Glaukos Corp to your portfolios can decrease your overall portfolio volatility.